Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

504

Participants

Timeline

Start Date

December 11, 2015

Primary Completion Date

September 15, 2017

Study Completion Date

November 24, 2023

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Nivolumab

DRUG

Docetaxel

Trial Locations (33)

0

Local Institution - 0008, Hangzhou

Local Institution - 0031, Beijing

Local Institution - 0049, Hong Kong

100021

Local Institution - 0051, Beijing

Local Institution - 0029, Beijing

100032

Local Institution - 0007, Beijing

100071

Local Institution - 0032, Beijing

100853

Local Institution - 0026, Beijing

105229

Local Institution - 0052, Moscow

119228

Local Institution - 0048, Singapore

121309

Local Institution - 0046, Moscow

130012

Local Institution - 0006, Changchun

130021

Local Institution - 0022, Changchun

194291

Local Institution - 0042, Saint Petersburg

197758

Local Institution - 0040, Saint Petersburg

198255

Local Institution - 0041, Saint Petersburg

200030

Local Institution - 0014, Shanghai

Local Institution - 0028, Shanghai

200032

Local Institution - 0017, Shanghai

200433

Local Institution - 0025, Shanghai

210000

Local Institution - 0034, Nanjing

308433

Local Institution - 0037, Singapore

310003

Local Institution - 0009, Hangzhou

310016

Local Institution - 0010, Hangzhou

350025

Local Institution - 0015, Fuzhou

400042

Local Institution - 0020, Chongqing

410008

Local Institution - 0023, Changsha

410013

Local Institution - 0012, Changsha

450008

Local Institution - 0024, Zhengzhou

454048

Local Institution - 0039, Chelyabinsk

510060

Local Institution - 0003, Guangzhou

510080

Local Institution - 0002, Guangzhou

610041

Local Institution - 0011, Chengdu

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY